L7 – Gynaecopathology: Hormonally-Driven Tumours of the Uterus Flashcards

1
Q

What are the typical features of the normal endometrial lining?

A

The endometrium is a cyclically regenerating mucosa with a proliferative basal layer and secretory functional layer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How is endometrial carcinoma generally classified?

A

It is broadly classified into Type I (low-grade, oestrogen-related, typically endometrioid carcinoma) and Type II (high-grade, non-oestrogen-related, such as serous and clear cell carcinomas).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which demographic is most affected by endometrial carcinoma?

A

It predominantly affects postmenopausal women, with the majority of cases occurring in women aged 60–70.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the precursor lesion for Type I endometrial carcinoma?

A

Atypical hyperplasia or endometrial intraepithelial neoplasia (EIN) is the recognised precursor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the key risk factors for endometrial carcinoma?

A

Risk factors include morbid obesity, chronic anovulation, late menopause, tamoxifen use, and a history of unopposed oestrogen exposure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does oestrogen influence the development of endometrioid carcinoma?

A

Excess oestrogen stimulates endometrial proliferation, increasing the risk of atypical hyperplasia and subsequent malignant transformation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the significance of hereditary syndromes in endometrial cancer?

A

Syndromes such as Lynch syndrome contribute to a higher risk of endometrial carcinoma due to germline mutations in mismatch repair genes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Why is the distinction between Type I and Type II endometrial carcinoma clinically relevant?

A

It guides treatment decisions and provides prognostic information, with Type I generally having a better prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What histological patterns are seen in endometrioid carcinoma?

A

They include confluent or back-to-back glands, cribriform or microacinar patterns, and occasional papillary formations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How do Type II carcinomas differ histologically from Type I?

A

Type II carcinomas, such as serous papillary and clear cell carcinomas, display high-grade nuclear atypia, papillary architecture, and more aggressive features.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What new molecular classification has emerged for endometrial carcinoma?

A

The integrated classification by TCGA divides tumours into groups based on POLE mutations, MMR deficiency, low copy number, and p53 abnormalities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does molecular profiling impact prognosis in endometrial carcinoma?

A

Molecular subtypes correlate with outcomes; for example, POLE-mutated tumours have an excellent prognosis, while p53 mutant tumours have a poor prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the primary symptom leading to the diagnosis of endometrial carcinoma?

A

Postmenopausal bleeding is the most common presenting symptom.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which factors are assessed to stage endometrial carcinoma?

A

Factors include myometrial invasion, lymphovascular space invasion, and the presence of extrauterine spread.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How does the depth of myometrial invasion influence prognosis?

A

Greater invasion correlates with higher risk of metastasis and poorer survival rates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What treatment options are available for endometrial carcinoma?

A

Treatment usually involves surgical management (hysterectomy with bilateral salpingo-oophorectomy) supplemented by radiotherapy, chemotherapy, or hormonal therapy as appropriate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What molecular markers help differentiate Type I from Type II endometrial carcinomas?

A

Type I often exhibits PTEN, KRAS, and PIK3CA mutations, while Type II frequently shows TP53 mutations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How does chronic anovulation contribute to endometrial carcinoma development?

A

Prolonged unopposed oestrogen exposure leads to continuous endometrial proliferation and increased mutation risk.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What role does endometrial intraepithelial neoplasia (EIN) play in carcinogenesis?

A

EIN represents a clonal expansion of atypical glands that is a direct precursor to invasive endometrioid carcinoma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How can imaging modalities like MRI aid in endometrial carcinoma staging?

A

They help assess myometrial invasion depth and extrauterine spread, guiding surgical planning.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the prognostic significance of lymphovascular space invasion in uterine cancers?

A

Its presence is linked to higher metastatic potential and a poorer prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What factors influence the decision to use adjuvant therapy in endometrial cancer?

A

Tumour stage, grade, depth of myometrial invasion, and molecular profile are critical in treatment planning.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How does tamoxifen use affect endometrial cancer risk in breast cancer patients?

A

Tamoxifen acts as an oestrogen agonist in the endometrium, increasing the risk of hyperplasia and carcinoma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is the primary challenge viruses face when entering a host cell?

A

Ensuring stability outside while rapidly disassembling inside the host.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How do viruses ensure stability outside the host while remaining capable of disassembly inside the host?

A

They remain structurally stable but utilize host factors to disassemble upon entry.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What entry mechanism do Adenoviruses and Influenza viruses commonly use?

A

Clathrin-mediated endocytosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What role does the ubiquitin system play in viral entry?

A

It labels proteins for degradation and regulates viral and cellular interactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What cellular structures act as transport highways for viruses?

A

Microtubules.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Which motor protein transports viruses toward the nucleus?

A

Dynein.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What is the genome type of Adenovirus?

A

Linear double-stranded DNA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

How does Adenovirus escape the endosome?

A

Through pH-dependent activation of viral proteins.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What viral protein is essential for Adenovirus endosomal escape?

A

Protein 6.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What process allows Adenovirus to reach the nucleus?

A

By traveling along microtubules using dynein motors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Which viral proteins are ubiquitinated to facilitate transport to the nucleus?

A

Key structural proteins of the virus.

36
Q

What are the main glycoproteins involved in Influenza virus attachment and entry?

A

Hemagglutinin (HA) and neuraminidase (NA).

37
Q

How does Influenza virus dismantle its structure upon entry?

A

Through acidification in the endosome, triggering fusion.

38
Q

Which host factor assists Influenza virus in uncoating its genome?

39
Q

How do Influenza genes enter the nucleus?

A

Using importin and transportin proteins.

40
Q

Why is nuclear transport crucial for Influenza virus replication?

A

Influenza replicates inside the nucleus, requiring nuclear entry of its RNA.

41
Q

How quickly do Adenovirus and Influenza complete their journey from entry to nuclear import?

A

Typically within 20 to 30 minutes.

42
Q

How does ubiquitination benefit viruses during entry and transport?

A

It helps viruses degrade host restriction factors and facilitates movement.

43
Q

Why is it important to understand the mechanisms viruses use to reach the nucleus?

A

It provides insight into viral replication and potential drug targets.

44
Q

What potential therapeutic strategies could target viral nuclear transport?

A

Blocking host factors involved in viral transport or disassembly.

45
Q

What are the typical features of the normal endometrial lining?

A

The endometrium is a cyclically regenerating mucosa with a proliferative basal layer and secretory functional layer.

46
Q

How is endometrial carcinoma generally classified?

A

It is broadly classified into Type I (low-grade, oestrogen-related, typically endometrioid carcinoma) and Type II (high-grade, non-oestrogen-related, such as serous and clear cell carcinomas).

47
Q

Which demographic is most affected by endometrial carcinoma?

A

It predominantly affects postmenopausal women, with the majority of cases occurring in women aged 60–70.

48
Q

What is the precursor lesion for Type I endometrial carcinoma?

A

Atypical hyperplasia or endometrial intraepithelial neoplasia (EIN) is the recognised precursor.

49
Q

What are the key risk factors for endometrial carcinoma?

A

Risk factors include morbid obesity, chronic anovulation, late menopause, tamoxifen use, and a history of unopposed oestrogen exposure.

50
Q

How does oestrogen influence the development of endometrioid carcinoma?

A

Excess oestrogen stimulates endometrial proliferation, increasing the risk of atypical hyperplasia and subsequent malignant transformation.

51
Q

What is the significance of hereditary syndromes in endometrial cancer?

A

Syndromes such as Lynch syndrome contribute to a higher risk of endometrial carcinoma due to germline mutations in mismatch repair genes.

52
Q

Why is the distinction between Type I and Type II endometrial carcinoma clinically relevant?

A

It guides treatment decisions and provides prognostic information, with Type I generally having a better prognosis.

53
Q

What histological patterns are seen in endometrioid carcinoma?

A

They include confluent or back-to-back glands, cribriform or microacinar patterns, and occasional papillary formations.

54
Q

How do Type II carcinomas differ histologically from Type I?

A

Type II carcinomas, such as serous papillary and clear cell carcinomas, display high-grade nuclear atypia, papillary architecture, and more aggressive features.

55
Q

What new molecular classification has emerged for endometrial carcinoma?

A

The integrated classification by TCGA divides tumours into groups based on POLE mutations, MMR deficiency, low copy number, and p53 abnormalities.

56
Q

How does molecular profiling impact prognosis in endometrial carcinoma?

A

Molecular subtypes correlate with outcomes; for example, POLE-mutated tumours have an excellent prognosis, while p53 mutant tumours have a poor prognosis.

57
Q

What is the primary symptom leading to the diagnosis of endometrial carcinoma?

A

Postmenopausal bleeding is the most common presenting symptom.

58
Q

Which factors are assessed to stage endometrial carcinoma?

A

Factors include myometrial invasion, lymphovascular space invasion, and the presence of extrauterine spread.

59
Q

How does the depth of myometrial invasion influence prognosis?

A

Greater invasion correlates with higher risk of metastasis and poorer survival rates.

60
Q

What treatment options are available for endometrial carcinoma?

A

Treatment usually involves surgical management (hysterectomy with bilateral salpingo-oophorectomy) supplemented by radiotherapy, chemotherapy, or hormonal therapy as appropriate.

61
Q

What molecular markers help differentiate Type I from Type II endometrial carcinomas?

A

Type I often exhibits PTEN, KRAS, and PIK3CA mutations, while Type II frequently shows TP53 mutations.

62
Q

How does chronic anovulation contribute to endometrial carcinoma development?

A

Prolonged unopposed oestrogen exposure leads to continuous endometrial proliferation and increased mutation risk.

63
Q

What role does endometrial intraepithelial neoplasia (EIN) play in carcinogenesis?

A

EIN represents a clonal expansion of atypical glands that is a direct precursor to invasive endometrioid carcinoma.

64
Q

How can imaging modalities like MRI aid in endometrial carcinoma staging?

A

They help assess myometrial invasion depth and extrauterine spread, guiding surgical planning.

65
Q

What is the prognostic significance of lymphovascular space invasion in uterine cancers?

A

Its presence is linked to higher metastatic potential and a poorer prognosis.

66
Q

What factors influence the decision to use adjuvant therapy in endometrial cancer?

A

Tumour stage, grade, depth of myometrial invasion, and molecular profile are critical in treatment planning.

67
Q

How does tamoxifen use affect endometrial cancer risk in breast cancer patients?

A

Tamoxifen acts as an oestrogen agonist in the endometrium, increasing the risk of hyperplasia and carcinoma.

68
Q

What is the primary challenge viruses face when entering a host cell?

A

Ensuring stability outside while rapidly disassembling inside the host.

69
Q

How do viruses ensure stability outside the host while remaining capable of disassembly inside the host?

A

They remain structurally stable but utilize host factors to disassemble upon entry.

70
Q

What entry mechanism do Adenoviruses and Influenza viruses commonly use?

A

Clathrin-mediated endocytosis.

71
Q

What role does the ubiquitin system play in viral entry?

A

It labels proteins for degradation and regulates viral and cellular interactions.

72
Q

What cellular structures act as transport highways for viruses?

A

Microtubules.

73
Q

Which motor protein transports viruses toward the nucleus?

74
Q

What is the genome type of Adenovirus?

A

Linear double-stranded DNA.

75
Q

How does Adenovirus escape the endosome?

A

Through pH-dependent activation of viral proteins.

76
Q

What viral protein is essential for Adenovirus endosomal escape?

A

Protein 6.

77
Q

What process allows Adenovirus to reach the nucleus?

A

By traveling along microtubules using dynein motors.

78
Q

Which viral proteins are ubiquitinated to facilitate transport to the nucleus?

A

Key structural proteins of the virus.

79
Q

What are the main glycoproteins involved in Influenza virus attachment and entry?

A

Hemagglutinin (HA) and neuraminidase (NA).

80
Q

How does Influenza virus dismantle its structure upon entry?

A

Through acidification in the endosome, triggering fusion.

81
Q

Which host factor assists Influenza virus in uncoating its genome?

82
Q

How do Influenza genes enter the nucleus?

A

Using importin and transportin proteins.

83
Q

Why is nuclear transport crucial for Influenza virus replication?

A

Influenza replicates inside the nucleus, requiring nuclear entry of its RNA.

84
Q

How quickly do Adenovirus and Influenza complete their journey from entry to nuclear import?

A

Typically within 20 to 30 minutes.

85
Q

How does ubiquitination benefit viruses during entry and transport?

A

It helps viruses degrade host restriction factors and facilitates movement.

86
Q

Why is it important to understand the mechanisms viruses use to reach the nucleus?

A

It provides insight into viral replication and potential drug targets.

87
Q

What potential therapeutic strategies could target viral nuclear transport?

A

Blocking host factors involved in viral transport or disassembly.